Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 463
2021 1403
2022 1703
2023 1445
2024 619

Text availability

Article attribute

Article type

Publication date

Search Results

4,910 results

Results by year

Filters applied: Clinical Trial. Clear all
Page 1
The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines.
Durusu Tanriover M, Altuntas Aydin O, Guner R, Yildiz O, Celik I, Kose S, Akhan S, Akalin EH, Ozdarendeli A, Unal S, Ates I, Kara A; TURKOVAC Study Group. Durusu Tanriover M, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2346388. doi: 10.1080/21645515.2024.2346388. Epub 2024 Jun 26. Hum Vaccin Immunother. 2024. PMID: 38924774 Free PMC article. Clinical Trial.
This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in Turkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vacci …
This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in …
Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial.
Huang T, Yu J, Zhang S, Teng D, Dai D, Zhu Y, Gao L. Huang T, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2330770. doi: 10.1080/21645515.2024.2330770. Epub 2024 Apr 11. Hum Vaccin Immunother. 2024. PMID: 38602539 Free PMC article. Clinical Trial.
Eligible healthy adults were randomly assigned (1:1) to receive QIIV at the same time as the first dose of COVID-19 vaccine (simultaneous-group) or 14 days after the second dose of COVID-19 vaccine (non-simultaneous-group). ...In conclusion, no immune …
Eligible healthy adults were randomly assigned (1:1) to receive QIIV at the same time as the first dose of COVID-19 vaccine (s …
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
Naficy A, Kuxhausen A, Seifert H, Hastie A, Leav B, Miller J, Anteyi K, Mwakingwe-Omari A. Naficy A, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2327736. doi: 10.1080/21645515.2024.2327736. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38513689 Free PMC article. Clinical Trial.
The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). ...Safety and reactogenicity profiles were similar in …
The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-admin …
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Budhawant C, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Poonawalla CS, Shaligram U, Kapse D, Gunale B. Kulkarni PS, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2304974. doi: 10.1080/21645515.2024.2304974. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38512394 Free PMC article. Clinical Trial.
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford Univ …
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vacci …
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
Roa CC Jr, de Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, Ilagan H, Ambrosino D, Siber G, Clemens R, Han HH. Roa CC Jr, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11. Hum Vaccin Immunother. 2024. PMID: 38206168 Free PMC article. Clinical Trial.
We assessed the non-inferiority of homologous boosting compared with heterologous boosting with the recombinant protein vaccine, SCB-2019, in adults previously immunized with different COVID-19 vaccines. Three equal cohorts (N ~ 420) of Philippino adults (18- …
We assessed the non-inferiority of homologous boosting compared with heterologous boosting with the recombinant protein vaccine, SCB-2019, i …
The effect of 5A self-management program on medication adherence of epileptic patients during the COVID - 19 pandemic: A randomized controlled trial.
Moosavimoghadam SF, Dehghani A, Akbar RE. Moosavimoghadam SF, et al. Acta Neurol Taiwan. 2024 Dec 30;33(4):165-174. Acta Neurol Taiwan. 2024. PMID: 37994005 Clinical Trial.
BACKGROUND: Adherence to medication adherence plays a vital role in controlling the problems and complications of epilepsy. During the COVID - 19 pandemic and limitations of face-to-face education, the use of distance education can play an important role in providin …
BACKGROUND: Adherence to medication adherence plays a vital role in controlling the problems and complications of epilepsy. During the CO
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C, Qiu Y, Wang J, Zhong X, Zhu X, Huang X, Yang L, Ji Q, Zhou F, Wu S, Yang M, Zhang J, Liu K, Ji L, Yang H, Li C, Zhao Y. Zhou C, et al. Emerg Microbes Infect. 2024 Dec;13(1):2320913. doi: 10.1080/22221751.2024.2320913. Epub 2024 Feb 29. Emerg Microbes Infect. 2024. PMID: 38860446 Free PMC article. Clinical Trial.
Continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enhanced transmissibility, significant immune escape, and waning immunity call for booster vaccination. We evaluate …
Continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
Liu Y, Zhang J, Liu W, Pan Y, Ruan S, Nian X, Chen W, Sun L, Yin Q, Yue X, Li Q, Gui F, Wu C, Wang S, Yang Y, Jing Z, Long F, Wang Z, Zhang Z, Huang C, Duan K, Liang M, Yang X. Liu Y, et al. Emerg Microbes Infect. 2024 Dec;13(1):2284297. doi: 10.1080/22221751.2023.2284297. Epub 2024 Mar 26. Emerg Microbes Infect. 2024. PMID: 37970736 Free PMC article. Clinical Trial.
No treatment-emergent adverse reactions of grade 3 severity or higher were reported. In the one-dose cohort, the 7-day cumulative SARS-CoV-2 infection rate was 79.0% in the F61 group and 82.6% in the placebo group, whereas, in the multiple-dose (once daily fo …
No treatment-emergent adverse reactions of grade 3 severity or higher were reported. In the one-dose cohort, the 7-day cumulative SARS
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Xu JW, Wang BS, Gao P, Huang HT, Wang FY, Qiu W, Zhang YY, Xu Y, Gou JB, Yu LL, Liu X, Wang RJ, Zhu T, Hou LH, Wang Q. Xu JW, et al. Emerg Microbes Infect. 2024 Dec;13(1):2281355. doi: 10.1080/22221751.2023.2281355. Epub 2023 Dec 30. Emerg Microbes Infect. 2024. PMID: 37933089 Free PMC article. Clinical Trial.
Vaccination strategies that can induce a broad spectrum immune response are important to enhance protection against SARS-CoV-2 variants. We conducted a randomized, double-blind and parallel controlled trial to evaluate the safety and immunogenicity of the biv …
Vaccination strategies that can induce a broad spectrum immune response are important to enhance protection against SARS-CoV- …
'Walk Buds': A walking intervention to increase physical activity, physical fitness, and emotional wellbeing, in 9-13 year old children with intellectual disabilities. Results of a clustered randomised feasibility trial.
Mullhall P, Taggart L, McDermott G, Slater P, Fitzpatrick B, Murphy MH, Hassiotis A, Johnston A. Mullhall P, et al. J Appl Res Intellect Disabil. 2024 Sep;37(5):e13260. doi: 10.1111/jar.13260. J Appl Res Intellect Disabil. 2024. PMID: 38937072 Clinical Trial.
CONCLUSION: A number of challenges were experienced, relating to the COVID-19 pandemic, and difficulties collecting accelerometer data. ...
CONCLUSION: A number of challenges were experienced, relating to the COVID-19 pandemic, and difficulties collecting accelerome …
4,910 results